Aisling Capital 13F annual report
Aisling Capital is an investment fund managing more than $45.3 million ran by Robert Wenzel. There are currently 5 companies in Mr. Wenzel’s portfolio. The largest investments include Aimmune Therapeutics and ADMA Biologics, together worth $42 million.
$45.3 million Assets Under Management (AUM)
As of 7th October 2020, Aisling Capital’s top holding is 1,240,000 shares of Aimmune Therapeutics currently worth over $26 million and making up 57.3% of the portfolio value.
Relative to the number of outstanding shares of Aimmune Therapeutics, Aisling Capital owns more than approximately 0.1% of the company.
In addition, the fund holds 3,608,171 shares of ADMA Biologics worth $16.1 million, whose value fell 15.1% in the past six months.
The third-largest holding is Cidara Therapeutics worth $1.78 million and the next is TransEnterix worth $1.48 million, with 2,389,352 shares owned.
Currently, Aisling Capital's portfolio is worth at least $45.3 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Aisling Capital
The Aisling Capital office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Robert Wenzel serves as the Chief Financial Officer at Aisling Capital.
Recent trades
In the most recent 13F filing, Aisling Capital revealed that it had opened a new position in
ViewRay and bought 18,964 shares worth $0.
On the other hand, Robert Wenzel disclosed a decreased stake in Aimmune Therapeutics by 0.4%.
This leaves the value of the investment at $26 million and 1,240,000 shares.
One of the smallest hedge funds
The two most similar investment funds to Aisling Capital are Pacific Life Insurance Company and Fiduciary Planning. They manage $45.1 million and $45.4 million respectively.
Robert Wenzel investment strategy
Aisling Capital’s portfolio is diversified across 1 sector.
Currently, their heaviest sector is Health Care — making up 100.0% of
the total portfolio value.
The fund focuses on investments in the United States as
100.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
20% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $608 million.
The complete list of Aisling Capital trades based on 13F SEC filings
These positions were updated on November 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Aimmune Therapeutics, Inc. |
37.69%
1,240,000
|
$25,966,000 | 57.34% |
| ADMA Biologics, Inc. |
No change
3,608,171
|
$16,056,000 | 35.46% |
| Cidara Therapeutics, Inc. |
12.69%
891,614
|
$1,779,000 | 3.93% |
| TransEnterix, Inc. |
No change
2,389,352
|
$1,481,000 | 3.27% |
| ViewRay, Inc. |
Opened
18,964
|
$0 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||
Hedge funds similar to Aisling Capital
- Clear Investment Research
- Encap Energy Capital Fund Viii Co-investors, L.P.
- Q Global Advisors
- Thompson Davis & Co., Inc
- Central Asset Investments & Management (hk) Ltd
- Colrain Capital
- Fiduciary Planning
- Pacific Life Insurance Company
- Cxi Advisors
- Smith Barney Fund Management
- Gresham Partners
- Yorktown Partners Viii, L.P.
- Qcm Cayman
- Monaco Asset Management Sam